PODD lowered guidance on higher type 2 attrition
PODD said it lowered guidance due to higher attrition in type 2 diabetes and softer new starts. The company cited corrective actions and innovations underway, expecting growth to moderate with stable pricing and continued international expansion.
Guidance was lowered because type 2 diabetes attrition has been higher and new starts have softened. Multiple corrective actions and innovations are underway, while growth is expected to moderate. The company said pricing remains stable and international expansion continues, with a robust pipeline intended to drive future adoption and r…